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1. Introduction 
Bronchiectasis is a constellation of diseases characterized by abnormally dilated bronchi 
with thickened bronchial walls due to repeated infection and inflammation. Bronchiectasis 
causes impairment of mucociliary clearance, airflow limitation, bronchorrhea, and 
predisposes to recurrent respiratory infections. It has a number of potential underlying 
causes. Laennec first described bronchiectasis as a distinct clinical entity in 1819 (Barker 
2002, O’Donnell 1998). The diagnosis, investigation and particularly management of 
bronchiectasis has been largely empirical and unfortunately, the subject of relatively few 
controlled clinical trials. Cystic fibrosis causes about a third of all bronchiectasis in United 
States (O’Donnell 1998), and is common worldwide. Cystic fibrosis (CF) is a recessive 
genetic disease characterized by dehydration of the airway surface liquid and impaired 
mucociliary clearance caused by altered functioning of a chloride channel called the Cystic 
Fibrosis Transmembrane Conductance Regulator (CFTR). Impaired chloride conductance 
through the apical portion of airway cells leads to dehydration of airway secretions causing 
lung destruction through obstruction of the airways with thickened secretions. The resultant 
endobronchial infection and exaggerated inflammatory response leads to the development 
of bronchiectasis (destruction and widening of airways) and progressive obstructive airway 
disease. This chapter provides insight into the specific diagnostic and therapeutic roles of 
bronchoscopy in patients with bronchiectasis and Cystic Fibrosis. 
2. Overview of bronchiectasis 
Bronchiectasis is generally defined as an abnormal and permanent dilatation of the bronchi 
with thickening of the bronchial wall. In a retrospective cohort study of the insurance claims 
made in United States, Weycker et al. showed the prevalence of bronchiectasis ranged from 
4.2 per 100,000 persons aged 18-34 years to 271.8 per 100,000 among those aged ≥75 years. 
Prevalence is higher among women than men at all ages (Weycker, D 2005). Bronchiectasis 
is being recognized with increasing frequency because of the widespread use of high-
resolution chest computed tomography (HRCT) scanning (Cohen, M 1999). A bronchus is 
thought to be dilated if on the CT scan the broncho-arterial ratio with the adjacent 
accompanying artery exceeds 1. There are many causes of bronchiectasis that can be 
classified as due to anatomic, systemic diseases, congenital, post infectious, or idiopathic 
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(Barker, A.F. 2002, O’Donnell, A.E. 2008). Table 1. Based on the HRCT, bronchiectasis can be 
classified into 3 types cylindrical bronchiectasis, varicose bronchiectasis and saccular or 
cystic bronchiectasis. In cylindrical bronchiectasis the bronchi fail to taper as the bronchi 
progress peripherally. Varicose bronchiectasis has an irregular and beaded appearance and 
appears as “a string of pearls”. Saccular or cystic bronchiectasis appears as a group of cysts 
without recognizable bronchial structures distal to the sacs (Webb, WR, High resolution CT 
chest of the Lung 2009). 
 
Post-Infectious 
Lower Respiratory Tract 
Granulomatous Infections 
Nectrotizing Pneumonias 
Other Respiratory infections 
 
Primary Immune Disorders 
Hypogammaglobulinemia 
Waldendstrom’s 
Other Humoral / Cellular Disorders 
Neutrophil abnormalities 
 
Heritable Structural Abnormalities 
Ciliated epithelium such as Primary 
Ciliary Diskinesia 
Cartilage or Connective Tissue 
(Tracheobronchiomegaly; Williams-
Campbell) 
Sequestration, agenesis, hypoplasia 
 
Idiopathic Inflammatory Disorders 
Sarcoidosis 
Rheumatoid Arthritis 
Systemic Lupus Erythematosis 
Sjogren’s Syndrome 
Inflammatory Bowel Disease 
Relapsing polychondritis 
Inhalational and Obstruction 
Severe Gastroesophageal Reflux 
Disease 
Chronic Aspiration Pneumonia 
Toxic or Thermal Inhalational Injury 
 
Cystic Fibrosis 
 
Young’s Syndrome 
 
Alpha1-Antitrypsin Deficiency 
 
Allergic Bronchopulmonary 
Aspergillosis 
Or Other Mycosis 
 
Post-obstruction 
Foreign body 
Tumor (benign and malignant) 
 
Miscellaneous 
HIV infection / AIDS 
Yellow Nail Syndrome 
Radiation Injury 
Table 1. Differential Diagnosis of Known Etiologies of Bronchiectasis 
Patients with bronchiectasis typically present with chronic cough recurrent infections and 
sputum production (Morrissey 2007). Recurrent infections lead to further airway 
inflammation and damage which worsens the condition. Other presentations include 
hemoptysis, chronic airflow obstruction, and slow progressive shortness of breath or 
dyspnea. Physical examination is variable based on the etiology. Bronchography was used 
in the past for visualization of bronchiectatic airways. This involved coating the airways 
with a radiopaque dye instilled through a catheter or a bronchoscope. However, with the 
advent of HRCT this procedure is rarely being utilized. Pulmonary function tests may show 
airflow obstruction. 
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Fig. 1. CT images of a patient with Yellow Nail Syndrome with pleural effusion. Yellow Nail 
Syndrome is characterized by slow growing curved thickened yellow nails with 
lymphedema, pleural effusion and bronchiectasis on Computed Tomography. Note the 
bronchiectatic airways in the right middle lobe. 
 
Fig. 2. Tracheobroncheomegaly or Mounier-Kuhn Syndrome. Images show marked 
dilatation of the trachea and the main stem bronchi. It is characterized by tracheal diameter 
greater than 3 cm that is measured 2 cm above the aortic arch. The right main bronchus 
should be greater than 2.4 cm and the left main bronchus greater than 2.3 cm. 
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Fig. 3. Plain radiograph of Kartagener’s Syndrome, characterized by situs inversus, 
azospermia, and bronchiectasis.  
 
Fig. 4. CT cross sections of a patient with Williams-Campbell syndrome which show 
bilateral cystic bronchiectasis distal to the third-generation bronchi with abnormal distal 
lucency probably due to air trapping hyperinflation of lung or bronchiolitis 
3. Overview of Cystic Fibrosis 
Cystic Fibrosis is the most common life-shortening genetic disease of Caucasians affecting 
more than 25,000 individuals in the United States. Cystic Fibrosis is an autosomal recessive 
disease due to alteration in the function of a chloride channel; the Cystic Fibrosis 
Transmembrane Conductance Regulator (CFTR) (Rowe S. M. 2005). In the setting of CFTR 
dysfunction, an inability of chloride to pass through the channel in the apical membrane of 
epithelial cells leads to less hydrated secretions from exocrine glands. In the lungs, this 
causes airway secretions to be thick and difficult to clear. In this milieu, inflammatory cells 
and colonizing bacteria clogging the airways leads to destruction and dilation with 
subsequent development of bronchiectasis. The bronchiectasis in patients with Cystic 
Fibrosis is classically an upper lobe process. However, over time, the destruction becomes 
widespread involving all lobes.  
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In addition to the development of bronchiectasis in individuals with Cystic Fibrosis through 
the pathophysiology of CFTR dysfunction, coincident bacterial and fungal colonization and 
infection propagate the airway dilation. Patients with Cystic Fibrosis are often colonized 
with atypical Mycobacterium (Whittaker, L. A 2009). Mycobacterium avium intracellulare is the 
most common such infection which leads to bronchiectasis in middle lobe and lingular 
segments. Moreover, Allergic Bronchopulmonary Aspergillosis affects up to 10% of CF 
patients leading to worsening central bronchiectasis (Laufer, P 1984, Knutsen A. P. 2011). 
The role of bronchoscopy in Cystic Fibrosis will be discussed herein.  
 
Fig. 5. CT image of right middle lobe involvement of Allergic Bronchopulmonary 
Aspergillosis with mucus impaction in a patient with Cystic Fibrosis. 
4. Role of bronchoscopy 
4.1 Role of diagnostic bronchoscopy in bronchiectasis 
Bronchoscopy is not routinely indicated for the diagnosis of bronchiectasis. With the 
increasing resolution and availability of high-resolution computed tomography (HRCT) 
scanning, the utility of bronchoscopy in patients with bronchiectasis is not clear, although 
there exist certain situations in which bronchoscopy provides vital information. 
Bronchoscopy for localized bronchiectasis is indicated to evaluate for the presence of an 
obstructing lesion causing distally located bronchiectasis when lobar or segmental 
bronchiectasis is apparant on CT imaging. For example, Middle Lobe Syndrome refers to the 
chronic collapse of the middle lobe which is often associated with distal middle lobe 
bronchiectasis. The etiology of Middle Lobe Syndrome has both infectious and non 
infectious causes. It can be divided into obstructive and non obstructive types (Albo, R.J. 
1966, Wagner RB 1983, Einarsson, J.T. 2009, ). Bronchoscopy is indicated in all patients with 
Middle Lobe Syndrome to evaluate for a compressing or obstructing lesion as malignancy is 
a common cause. (Albo, R.J. 1966, Wagner R.B. 1982, Priftis, K.N. 2005,). Foriegn body may 
not be apparant on HRCT. Dikensoy et al in their review of foreign body aspiration reported 
cases of foreign body seen at bronchoscopy which was not evident on CT of the chest 
(Dikensoy, O. 2002). Cytological examination of bronchoscopic specimens can provide 
evidence supporting gastric aspiration as a cause of bronchiectasis in dependent lung 
segments(Pasteur, M.C. 2010). Li et al showed 3/4 cases of bronchiectasis thought to be due 
to aspiration had lipid-laden macrophages on cytology (Li, A.M. 2005) 
www.intechopen.com
 
Global Perspectives on Bronchoscopy 112 
The British Thoracic Society published guidelines related to the utility of bronchoscopy in 
non-Cystic Fibrosis Bronchiectasis in 2010, which lists several indications for diagnostic 
bronchoscopy (Pasteur, M.C. 2010). Table 2. 
Pasteur et al identified a study by Fernald at el in 1978 in stable state in which bronchoscopy 
did not show any advantage over sputum culture at identifying lower respiratory tract 
pathogens (Pasteur, M.C. 2010 Fernald G.W., 1978). Shiekh et al retrospectively evaluated 
the occurence of bronchiectasis in children with HIV pneumopathy (Shiekh, S. 1997 ). They 
found that bronchoalveolar lavage (BAL) had a high yield of clinically relevant information 
that required specific treatment. 22/57 (38.6%) were positive of Pneumocystis carinii, 14/27 
(24.5%) had CMV and 12/27 (21%) were positive for MAI.  
 
Table 2. British Thoracic Society Guidelines on non-Cystic Fibrosis Bronchiectasis 
Pang et al while evaluating the bacteriology of bronchiectasis in Hong Kong, concluded that 
BAL and protected specimen brush are comparably sensitive in detecting lower respiratory 
tract organisms (Pang, J.A. 1989). Cabello et al looked at distal airway flora of healthy 
subjects with chronic lung disease including those with bronchiectasis and found that 88% 
of patients had bacterial colonization (Cabello, H. 1997). They also found comparable 
sensitivities between both BAL and protected specimen brush. Tanaka et al found that 
bronchial washings was twice as sensitive as expectorated sputum for isolation of 
Mycobacterium avium complex (Tanaka, E. 1997). They also went on to show that 
granuloma formation as seen on lung biopsy would suggest infection rather than 
colonization. 
Bronchoscopy in the setting of Tuberculosis is a vast topic and is beyond the scope of this 
chapter, however, a brief review is warranted. In endemic areas, a positive sputum acid-fast 
bacilli (AFB) smear is frequently regarded as diagnostic of pulmonary tuberculosis. 
Negative AFB smears often poses a diagnostic challenge. Tan et al examined the clinical 
utility of rapid Mycobacterium tuberculosis (MTB) detection in bronchoalveolar lavage 
(BAL) samples by polymerase chain reaction (PCR). BAL PCR had sensitivity, specificity, 
positive and negative predictive values of 66.7%, 100%, 100% and 88%, respectively, for the 
group with upper lobe infiltrates (Tan YK 1999). Ismail and coworkers reviewed 232 cases of 
1. Bronchiectasis in a single lobe to exclude a foreign body obstruction especially in 
children;  
2. In adults with localized disease, bronchoscopy may be indicated to exclude 
proximal obstruction;  
3. Bronchoscopy is useful for obtaining microbiological results in patients who are 
acutely ill; 
4. Bronchoscopic sampling of lower respiratory tract secretions may be indicated in 
patients with bronchiectasis in whom serial sputum testing is not yielding results 
and who are worsening;  
5. Bronchoscopy can be used to obtain endobronchial biopsy of airway cilia to 
investigate causes of bronchiectasis  
6. Bronchoscopy can be used to localize the site of bleeding in patients with 
bronchiectasis and hemoptysis which can guide further interventional therapies.  
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pulmonary tuberculosis and found that 22.8 % of patients had smear positive acid fast 
bacilli, 11.2 % of patients were diagnosed with tuberculosis based on this. In the setting of 
negative sputum testing in patients with typical clinical and chest radiographic 
presentations, the diagnostic accuracy was improved to 49.1% with bronchoscopic 
washings. Twenty-four percent of these demonstrated smear positivity and the other 25% 
were culture positive (Ismail Y 2004). Watanuki et al. examined 14 subjects with abnormal 
chest radiographs in which no definite diagnosis could be obtained through sputum 
analysis including smears and cultures. Bronchoscopic washings were positive for 
Mycobacterium in 7 patients on smear while cultures were positive in 8 patients. 
Mycobacterium avium complex (MAC) was identified in 13 patients; however, only 36% of 
those tested by specific polymerase chain reaction probes were MAC-positive. In patients 
undergoing transbronchial lung biopsy (n=11), histological review showed granuloma 
formation in four and caseation in another three patients (Watanuki Y 1999). Watanabe 
described 19 cases of bronchial stricture or obliteration due to endobronchial tuberculous 
lesions. Based on their findings, these authors recommended bronchoscopy and computed 
tomography as methods of choice for accurate diagnosis of tuberculous bronchial 
involvement (Watanabe Y 1997). Moreover, these modalities may aid in the assessment for 
surgery. Based on review of the available literature focusing on Tuberculosis or other 
Mycobacterial infections in the setting of bronchiectasis, bronchoscopy should be considered 
when diagnosis is uncertain in high-risk patients or when assessment of intervention is 
necessary.  
4.2 Role of bronchoscopy in Cystic Fibrosis 
Most of the current literature about the use of bronchoscopy in Cystic Fibrosis comes from 
pediatric experience. In infants with asymptomatic CF and those diagnosed through 
newborn screening, bronchoscopy is useful in defining bacterial colonization and 
inflammation in the airways not obtainable through less invasive means (Rosenfeld, M. 
2001). The high yield of microbiology, cytology, and pH probe investigations in newborn 
infants with CF suggests that invasive surveillance fiber optic bronchoscopy (FOB) should 
be considered (Stafler, P. 2001). Bronchoscopy has been used for studying inflammatory 
markers such as Interleukin -8 and nitrite in the lower airway of patients with Cystic 
Fibrosis (Noah, T.L. 2003, Cetin, I. 2004, Davis, S.D. 2007, Cobanoglu, N. 2010). 
Bronchoscopy has similarly been used for identification of atypical airway infections. Semi 
quantitative culture of bronchoalveolar lavage (BAL) fluid was a useful diagnostic tool in CF 
patients in whom empiric therapy failed (Baughman, R.P. 1997). Dahm et al. showed 
fiberoptic bronchoscopy to be a superior technique for obtaining BAL samples as compared 
to rigid bronchoscopy or bronchial washout (Dahm, L.S. 1977). Davis et al. showed that the 
BAL fluid inflammation as indicated by the percent of recovered neutrophils and 
Interleukin -8 levels was significantly higher in the area identified as having the greatest 
disease on a high resolution chest CT (Davis, S.D. 2007). This highlights the potential 
importance of performing BAL in more than one area in patients with CF. In a retrospective 
study, Gilchrist et al showed that single-lobe bronchoalveolar lavage is not sufficient in 
assessing patients with cystic fibrosis for lower airway infection (Gilchrist, F.J. 2011). Studies 
have also compared sputum versus BAL in CF (Aaron, S.D. 2004). Bronchoscopy has been 
used to localize the site of bleeding in patients with CF-related hemoptysis, although there is 
little evidence for its benefit (Flume, P.A. 2010). 
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4.2.1 Role of Bronchoalveolar Lavage (BAL) in bronchiectasis and CF  
There is evidence of early functional structural and pathological changes including 
bronchiectasis in babies with CF (Linnane, B.M. 2008, Linnane, B.M., Hall G.L.2008). Hillard 
et al in UK showed that 44% of asymptomatic children investigated with Bronchoscopy and 
BAL had a positive culture prior to newborn screening (Hillard, T.N. 2007). While looking at 
the patient’s after newborn screening they found 27% of asymptomatic patient’s had 
positive BAL cultures. There was evidence of airway inflammation as well. Whether early 
identification and aggressive treatment of asymptomatic pulmonary infections delays the 
decline in lung function is a matter of debate and at the present time there are no 
longitudinal studies. In a retrospective review of bronchoscopies performed in pediatric 
cystic fibrosis patient’s Boogarard et al showed that 28/66 (42%) of the BAL provided 
information that had therapeutic consequences (Boogaard, R. 2008). The European 
Respiratory Society guidelines in 2000 recommended taking one BAL specimen from the 
most effected lobe or the right middle lobe (de Blic J 2000). This was later changed to two 
BALs specimens in 2007 (Brennan, S. 2008). In a retrospective review Gilchrist et al found 
that if they have used the 2000 ERS guidelines of only sampling a lobe they could have 
missed 26 positive cultures, while if they used the most current or 2007 guidelines for BAL 
sampling with 2 BALS at 2 different lobes then they would have missed only 12 positive 
cultures out of 39 (Gilchrist, F.J. 2011). 
 
Fig. 6. CT image of a 24-year-old female with Cystic Fibrosis. The patient had frequent 
pulmonary exacerbations of Cystic Fibrosis and progressive decline in lung function in spite 
of aggressive appropriate antibiotic therapy guided by expectorated sputum cultures. She 
subsequently underwent a directed bronchoscopy with BAL in the right middle lobe (arrow) 
which grew Mycobacterium abscessus. Treatment of this infection broke the cycle of recurrent 
pulmonary exacerbations.  
BAL has also been compared to oropharyngeal swabs to determine the pathogen causing 
sinus infection by Muhlebach et al. Sinusitis can cause CF exacerbations. The diagnostic 
accuracy of BAL and oropharyngeal swabs cultures was low in predicting sinus infections 
especially at younger ages. The positive predictive value of BAL sample for Pseudomonas 
aeruginosa infection was 65% while the negative predictive value was 67%. These were 
similar to oropharyngeal swab cultures. The positive predictive value for Staphylococcus 
aureus was 76% and a negative predictive value was 63% for the BAL fluid. Based on this 
study both BAL and oropharyngeal swabs are poor predictors of the organisms present in 
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the sinus (Muhlebach, M.S. 2006). In the Australasian Cystic Fibrosis Bronchoalveolar 
Lavage randomized controlled trial cystic fibrosis patients identified through newborn 
screening were randomly assigned to BAL directed therapy versus standard therapy 
(Wainwright, C.E. 2011). They reported similar prevalence of Pseudomonas and other 
organisms amongst the two groups. There were no significant differences in the secondary 
outcomes such as FEV1, weight or BMI amongst the two groups. BAL fluid in cystic fibrosis 
patients has also been used to quantify and assess BAL fluid nitrite levels as this may reflect 
adequate the degree of inflammation in the respiratory tract and could potentially be a 
useful indicator of airway inflammation for patients with CF (Cetin, I 2004). 
Cobanoglu et al studied the levels of ANCA in serum and BAL fluid to identify any 
relationship with infection (Cobanoglu, N 2010). MacGregor et al analyzed the BAL fluid 
obtained from CF patients using mass-spectrometry techniques (MacGregor, G 2008). 
4.2.2 Role of protected brushing in bronchiectasis and CF 
Bronchoscopy with protected Brush has been used to collect uncontaminated airway specimen 
for culture from the lower airways. As the brush is used to directly obtain secretions and 
bacteria from the airway lumen and then retracted into a sterile sheath, it is thought to have 
minimal contamination from other airway secretions. Aaron et al (2004) tried to see if 
bronchoscopy with protected brush would sample biofilm-forming bacteria on the airway wall 
as opposed to traditional sputum collection techniques. A total of 12 patients were evaluated 
with protected brush bronchoalveolar lavage and expectorated sputum collection. They 
showed that 10 patients (83%) had the same strain of Pseudomonas aeruginosa found using all 3 
techniques. They concluded that sputum collection provided as much information for 
characterization and antibiotic susceptibility testing of Pseudomonas aeruginosa infection as 
bronchoscopy with protected brush (Aaron, S.D. 2004). As mentioned in previous sections 
Pang et al as well as Cabello et al showed that protected brush specimen was comparably 
sensitive to bronchoalveolar lavage in detecting lower respiratory tract organisms in patients 
with bronchiectasis (Pang, J.A. 1989, Cabello, H. 1997). 
4.2.3 Role of endobronchial and transbronchial biopsy in bronchiectasis and CF 
Endobronchial biopsy during bronchoscopy is a minimally used technique in the diagnostic 
evaluation of patient’s with cystic fibrosis. There is a theoretical concern of bleeding with 
endobronchial biopsy in these patients due to increased blood flow. Endobronchial biopsy 
has been used safely in adults with cystic fibrosis during research protocols. Molina-Teran et al 
retrospectively looked at 45 bronchoscopies with endobronchial biopsies in children with 
cystic fibrosis at their Institute and matched them to control. They noted 6/45 (13%) had 
complications during the procedure of which 4 had significant coughing, 1 had > 10 % drop in 
oxygen saturation which improved with oxygen and 1 had dental loss. During the 12 hours 
after the procedure there was no significant complications in both patients with cystic fibrosis 
and the controls. They did not note any significant bleeding (Molina-Teran, A. 2006). One of 
the drawback of this study is that they is did not quantify the bleeding. Patients with severe CF 
were excluded from the study. In 2007 Regamey et al prospectively assessed the quality of the 
biopsy specimen obtained from children with cystic fibrosis using non-CF patients as control. 
They concluded that adequate biopsy specimens could be obtained to study the airway of 
patients with cystic fibrosis (Regamey, N. 2007). They did suggest taking at least 2 biopsies and 
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the use of large forceps during the biopsy procedure. As mentioned earlier, in patients with 
bronchiectasis with suggestion of MAC on HRCT Tanaka et al found that 10/26 who 
underwent transbronchial lung biopsy had granuloma formation, 8 of whom were positive for 
MAC and 2 were positive for M. abscessus and M. fortuitum. They showed that this was present 
with infection and not with colonization (Tanaka, E. 1997). 
We can conclude that in the bronchial biopsy can be used safely as a diagnostic tool in the 
evaluation and management of patient’s with Cystic Fibrosis and bronchiectasis. In the setting 
of uncertainty in CF, it can yield important information leading to therapeutic guidance. 
4.3 Role of bronchoscopy for therapeutics 
Despite the paucity of literature in bronchoscopy for patients with cystic fibrosis and 
bronchiectasis there are reports of its therapeutic use. Lobar atelectasis is a common 
complication in patients with cystic fibrosis. Morbidity and mortality of patient’s with cystic 
fibrosis has been linked to their FEV1. As such the consequences of persistent atelectasis in 
these patients can be serious (Stern, R.C. 1978). Whitaker et al reported a case series of CF 
patients with Allergic Bronchopulmonary Aspergillosis (ABPA) who successfully 
underwent sequential bronchoscopy with installation of recombinant human DNase to 
achieve re-expansion of the lung after they had failed standard medical therapy (Whitaker, 
P. 2011). McLaughlin et al. successfully treated lobar atelectasis in CF patients with ABPA, 
which was resistant to conventional therapy with antibiotics and chest physiotherapy, with 
bronchoscopic instillation of recombinant human deoxyribonuclease (rhDNase) 
(McLaughlin, A.M. 2008). Slattery et al also showed similar results in another retrospective 
study. They showed therapeutic bronchoscopy with rhDNase lavage was shown to be safe 
and associated with improved chest radiographs in pediatric CF patients with persistent 
atelectasis (Slattery, D.M. 2001). 
 
Fig. 7. CT image of a 42-year-old woman with Cystic Fibrosis with recurrent massive 
hemoptysis. Initially based on imaging, a left-sided source was assumed and she underwent 
bronchial artery embolization (BAE). As hemoptysis was unremitting, bronchoscopy was 
performed to localize the source, which was identified and successfully treated with BAE of 
the right upper lobe vessels. 
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Bronchomalacia or collapse of the large airway is only rarely reported as a complication of 
CF. Herlitz et al. were the first to report the successful deployment of an expandable silicone 
stent to treat bronchomalcia in a 15 year old with CF (Herlitz, G.N. 2006). This led to clinical 
improvement as well as improvement in the pulmonary function test obviating the 
immediate need for lung transplant. Bronchoscopy and transbronchial stenting have been 
used to treat complications arising from lung transplantation or surgery in patients with 
cystic fibrosis. Wood at al reported a case of a 20-year-old with cystic fibrosis who came 
with recurrent massive hemoptysis that was due to bronchopleural fistula at the stump site. 
They used superglue (butyl or Methy methacrylate) passed through a Teflon catheter 
through the working channel of the bronchoscope to seal the stump (Wood, R.E. 1992). 
Bronchoscopy has been used in management of hemoptysis in patients with CF and 
bronchiectasis. Joseph at al used bronchoscopic techniques for gene transfer to airway 
epithelium using adenoviruses for cystic fibrosis (Joseph, P.M. 2001, Perricone, M.A. 2001). 
5. Safety of bronchoscopy in Cystic Fibrosis 
Adverse events are common with BAL in young CF children, but are usually transient and 
well tolerated (Wainwright, C.E. 2008). Wainwright at al conducted a prospective multi-
center study to systematically evaluate safety and adverse events associated with BAL in 
pediatric CF patients. They looked at pediatric patients undergoing BAL between September 
1999 and December 2005. Twenty-nine of 333 (8.7%) of the BALs were followed by fever; 10 
(3%) had clinically significant deterioration of which five required assisted ventilation 
during the procedure due to desaturation; one had a ventricular tachyarrhythmia after the 
use of an anesthetic agent; and one was hospitalized for stridor and respiratory distress. The 
rates of patients with fever in this study were no different than the rates reported in other 
studies in children without CF. Transient fever after BAL is thought to be associated with 
elevated serum pro inflammatory markers and can develop without bacteremia. They did 
find that focal bronchitis was associated with clinically significant deterioration during or 
after the BAL procedure, the reason for which were not entirely clear. Another strong 
association noted was between Streptococcus pneumonia in BAL fluid and fever afterwards. 
Worsening of cough was the most frequently reported minor event. It did not result in any 
increase in hospitalization. As mentioned previously, in a retrospective review Molina-
Teran et al. showed that endobronchial biopsy performed under general anesthesia can be 
done safely in children with CF (Molina-Teran, A. 2006). They noted 6/45 (13%) had 
complications during the procedure of which 4 had significant coughing, 1 had > 10 % drop 
in oxygen saturation which improved with oxygen and 1 had dental loss. During the 12 
hours after the procedure there was no significant complications in both patients with cystic 
fibrosis and the controls. They did not note any significant bleeding. The major drawback of 
this study was that it did not quantify the bleeding or include patients with severe disease. 
Endobronchial biopsy has been performed safely in adult CF patients for the purpose of 
research. 
6. Role of anaesthesia and sedation 
As with all procedures, the safety of the patient is paramount. Decisions regarding the best 
approach for patient control and comfort surround multiple patient factors as well as 
consideration for the duration and technical aspects of the procedure. Conscious sedation is 
www.intechopen.com
 
Global Perspectives on Bronchoscopy 118 
performed by many providers performing bronchoscopies on patients with bronchiectasis 
and cystic fibrosis. However, due to profound bronchoscopasm often experienced with 
airway manipulation, consideration for the utilization of anesthesia support should strongly 
be considered in patients with bronchiectasis and cystic fibrosis.  
Little was known initially about the role of general anesthesia in patients with Cystic 
Fibrosis. Price showed that a marked deterioration in lung function took place after a brief 
anesthetic for a relatively minor surgical procedure (Price, J.F. 1986). In a retrospective 
review, Chhajed et al showed that the sedative drug requirements during bronchoscopy 
were higher in patients with CF, especially after lung transplantation (Chhajed, P.N. 2005). 
Few authors reviewed the preoperative assessment, intraoperative and postoperative 
management of patients with CF (Huffmyer, J.L. 2009, Della Rocca, G. 2002, Walsh, T.S. 
1995). An anesthetic plan for patients with CF undergoing procedures was described by 
Karlet et al (Karlet, M.C. 2000).  
The respiratory dysfunction associated with cystic fibrosis should be the major focus of 
preoperative evaluation by the anesthesiologist. The anesthesiologist should quantify the 
level of pulmonary function and extent of cardiopulmonary limitation preoperatively and 
attempts must be made to optimize it prior to the procedure. Historically, the amounts of 
sputum production, decreased exercise tolerance, decreasing weight are important features. 
If patients report an increased cough, wheezing, increased sputum production, decreased 
activity level, infection or other symptoms to suggest CF exacerbation, admission to the 
hospital for optimization of lung function should be considered. Hypercarbia typically 
develops late in cystic fibrosis.  
All cases should receive chest radiograph, pulmonary function testing, serum electrolyte 
levels including blood glucose levels, complete blood cell count and liver function tests 
(Della Rocca, G. 2002). Depending on the type of bronchoscopy being performed and the 
patient's history of liver involvement, further coagulation testing may be ordered. 
Moreover, arterial blood gas measurements, electrocardiogram, and echocardiogram may 
also be performed prior to the procedure if warranted by the patient’s history. 
Patient's routine medications including bronchodilators and corticosteroids should be 
continued into the perioperative period. Sedatives and analgesics should be used cautiously 
in the preoperative period as they can depress the respiratory drive and patient's inability to 
clear secretions (Huffmyer, J.L. 2009). Premedication with an antacid such as H2 blocker 
should be considered as there is a higher incidence of gastroesophageal reflux (Weeks, A.M. 
1995). 
Procedural monitoring should include continuous electrocardiography, respiratory rate, 
oximetry, and blood pressure. Capnography may be beneficial in patients requiring 
significant sedation or in those with moderate to severe lung disease. Arterial blood gas 
monitoring should be performed for patients with severe disease. Frequent intraoperative 
and postoperative management of blood sugars is indicated for prolonged procedures. 
Ventilating pressures should be monitored carefully as patients with CF are at risk for 
rupture of emphysematous bullae resulting in a pneumothorax (Karlet, M.C. 2000) in the 
setting of air trapping. 
Preoxygenation to achieve higher oxygen saturation before induction is important. History of 
significant gastroesophageal reflux would require a rapid sequence induction. The short life of 
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Propofol makes it an ideal choice. Ketamine is relatively contraindicated due to increased 
bronchial secretions. The advantage of volatile inhalational agents used in general anesthesia is 
that they cause bronchodilation, decrease muscle relaxant dosage, and reduced airway 
hyperreactivity. Although Desflurane has an undesired pungent odor and respiratory tract 
irritability which makes it a poor choice of agent. Systemic hydration and humidification of 
inspired gasses are important for maintaining secretions in a less viscous state. If muscle 
relaxants are used short-acting nondepolarizing agents may be more appropriate. They should 
be administered in minimum possible doses. It should be noted that the aminoglycoside 
antibiotics use to treat infections might prolong the neuromuscular blocking affect. Extubation 
should be delayed until the effect of muscle relaxants has worn off. 
Anesthesia should be tailored towards rapid postoperative recovery of the ability to cough 
and take deep breaths to actively clear secretions. Post procedure aggressive suctioning, 
chest physiotherapy and oxygen supplementation should be continued till the effect of the 
anesthetic agent has worn off and patient is back to his/her previous state of health. 
 
Suggested tests 
 
Serum electrolytes 
Complete blood count 
Liver function tests 
Chest X ray 
Pulmonary function tests 
Blood glucose levels 
Electrocardiogram 
Further testing 
 
Coagulation tests 
Arterial blood gas 
Echocardiogram 
Adapted from Karlet, 2002 
Table 3. Preoperative test for Anesthesia 
7. Approach to performing bronchoscopy in bronchiectasis and CF 
Preparation for bronchoscopy in patients with cystic fibrosis or chronic suppurative 
bronchiectasis is similar to the initial evaluation for anaesthesia. Important aspects include a 
clear understanding of the indication for bronchoscopy. As the pulmonologist 
understanding the current and usual steady state of the patients’ respiratory function is 
critical. While there are no clear guidelines to support peri-operative antibiotics these 
patients may have a higher likelihood of transient bacteraemia or post bronchoscopic febrile 
episodes. Judicious clinical judgement of the patients overall condition should be followed 
in determining which patients may benefit from peri-operative antibiotics.  
Having a clear understanding of the indications for the procedure in these patients is not 
only important in weighing risk and benefit but in allowing an expeditious procedure. 
Patients with advanced obstructive lung disease may have difficulty with hypoxemia and 
other complications. A well planned procedure will shorten the duration and attempt to 
mitigate risk. 
If the indication is for airway sampling for culture, care must be taken to avoid 
contamination of the cultures by suctioning in the upper airway. This may be difficult due 
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to the tenacious sputum and upper airway secretions in patients with cystic fibrosis. This is 
usually less of an issue in those with suppurative bronchiectasis. Strong consideration 
should be given to protected brush specimen retrieval in all these patients. Ensuring rapid 
and appropriate transport to the laboratory and rapid plating will significantly aid in 
obtaining viable culture specimens.  
Patients with chronic suppuration coincident with bronchiectasis may have mucosa that is 
particularly friable. Having a seasoned bronchoscopist is the best choice to avoid mucosal 
injury and provide the shortest procedural time. These patients are likely not the best 
candidates for early trainees in bronchoscopy or those who rarely perform bronchoscopy. 
When these patients present with haemoptysis localization may be critical to guiding 
bronchial or intercostals arterial embolization. In addition, visualization of a more proximal 
bleed can occasionally occur. In these cases endobronchial therapies are warranted. The 
authors would recommend non contact therapies such as argon plasma coagulation or very 
low wattage Nd:YAG laser. If the indication for the bronchoscopy is mucosal sampling for 
ciliary dyskinesias a critical step is ensuring the correct specimen handling procedures are 
known and strictly followed. Most laboratories do not routinely process specimen’s electron 
micrography. Ensuring good pre-procedural communication cannot be understated. 
With the advancing population age of cystic fibrosis patients and the presence of 
bronchiectasis in middle age or older individuals the potential of central airway obstruction 
must be considered. Both primary bronchogenic carcinoma and metastatic airway disease 
may occur. Therapeutic bronchoscopy should be considered for these patients if central 
airway obstruction is due to endobronchial tumor. Therapeutic decision-making, such as 
risk to benefit of placing a endobronchial foreign body in a suppurative airway makes these 
cases extremely challenging. The authors would recommend referral to an interventional 
pulmonologist in a “center of excellence” to provide the best care for these complicated 
patients. Endoluminal ablative therapies are not contraindicated in these patients but 
experience is fairly limited. A center with a high volume of therapeutic bronchoscopy is 
likely the best choice. 
8. Conclusions 
Bronchoscopy provides useful diagnostic information in patients with bronchiectasis and 
Cystic Fibrosis. The use of these techniques aids the clinician in preventing the considerable 
morbidity associated with these conditions, and a proper understanding of the intricices of 
bronchoscopic procedures in these patients is paramount to success. 
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